Trial Profile
A phase I/II study of concurrent chemoradiotherapy with irinotecan for advanced or recurrent uterine cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jan 2012
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Antineoplastics
- Indications Uterine cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Jan 2012 New trial record